Quality and Compliance Key Points for Primary Antibody Raw Materials in In Vitro Diagnostic Reagents

The Role of Primary Antibodies in In Vitro Diagnostic Reagents

In in vitro diagnostic reagents, primary antibodies are often used as capture or detection antibodies for platforms such as immunochromatography, chemiluminescence, and enzyme-linked immunosorbent assay. Their quality directly affects the sensitivity, specificity, and stability of diagnostic reagents. During the research and development stage, it is necessary to systematically evaluate the raw material sources, immunogen design, and purification processes of primary antibodies in accordance with the intended clinical use, ensuring they meet product design requirements.

Key Quality Attributes and Technical Specifications

Primary antibodies for in vitro diagnostics require attention to affinity, specificity, purity, and batch-to-batch consistency. Generally, antibodies are required to recognize native or recombinant antigens at target concentrations without significant cross-reactivity with similar interferents. Batch-to-batch consistency can be evaluated through performance comparison of multiple pilot batches. For quantitative detection, it is also necessary to assess whether the reaction curves of primary antibodies with calibrators and quality control materials are stable.

Supplier Management and Raw Material Change Control

Manufacturers should establish a primary antibody supplier audit system, focusing on the supplier's production processes, quality system, and supply capacity. Primary antibodies are key raw materials, and changes may affect product performance; therefore, change verification must be conducted in accordance with relevant regulations and quality management system requirements. Common practices include retention sample comparison, performance testing, and stability studies, with change registration applications to regulatory authorities when necessary.

Stability Studies and Registration Dossier Preparation

Stability studies of primary antibodies should cover raw material storage, working solution preparation, and finished product shelf life. Generally, the effects of temperature, freeze-thaw cycles, and buffer systems on antibody activity need to be evaluated. The registration dossier should include descriptions of primary antibody sources, clone information, purity testing, and quality standards, but should not involve trade secrets. Through comprehensive quality research, support can be provided for the compliant market launch of in vitro diagnostic reagents.